Kaposi's sarcoma

Kaposi's sarcoma ( [ kɒpoʃi ] ) is an occurring mainly in the context of AIDS cancer, the cause of the human herpes virus type 8 (HHV -8) is most likely due in connection with cofactors. The necessity of cofactors to the emergence of the disease arises from the fact that HHV -8 is much more widespread even than Kaposi's sarcoma. Among the cofactors include on current perception immunosuppression, environmental factors and oxidative and nitrosative stress.

It was built in 1872 by Moritz Kaposi ( 1837-1902 ), a Viennese dermatologist Hungarian origin first described, and is named after him. It is a function of a weakened immune system of the host. The disease manifests itself by the appearance of brown - bluish tumor nodules mainly in the area of mucous membranes and in the intestine. Basically, men are affected more often than women. When associated with AIDS form brown - bluish spots occur multifocal usually also on the skin of the legs and arms.

Diagnosis

The diagnosis is made on the clinical picture and if in doubt about a histological preparation.

Course

The course is often chronic. A metastasis formation in lymph nodes and other organs is possible. Also possible is a rare, direct infection of the lymph vessels with subsequent spread to internal organs in the absence of HIV Association.

After transplantation there is an increased risk of disease due to the weakened immune system by immunosuppressive drugs. The disease attacks the internal organs directly here and shows no symptoms of the skin.

Therapy

In the treatment of Kaposi's sarcoma, it is primarily important to maintain the function of the immune system, which is why in HIV and AIDS patients, the antiviral combination therapy is of utmost importance. The same is true for transplant. Here, a change of immunosuppressive therapy lead to regressions of Kaposisarkoms.

Additional therapeutic approaches:

• Local therapies: excision, laser therapy, radiation therapy, physical therapy.
• Chemotherapy: Liposomal -encapsulated doxorubicin or daunorubicin.
• Experimental: anti- angiogenesis therapy ( SU5416 ), interferon - alpha, thalidomide.

Swell

• SR Mallery, P. Pei, DJ Landwehr, CM Clark, JE Bradburn, GM Ness, FM Robertson: Implications for oxidative and nitra tive stress in the pathogenesis of Kaposi 's sarcoma AIDS-related; Carcinogenesis 25 (2004); Pp. 597-603; PMID 14656937
• SR Mallery, RT Bailer, CM Hohl, CL Ng - Bautista, GM Ness, BE Livingston, BL Hout, RE Stephens, GP Brierley: Cultured AIDS-related Kaposi 's sarcoma (AIDS -KS ) cells demonstrate impaired Bioenergetic adaptation to oxidant challenge: implication for oxidant stress in AIDS -KS pathogenesis; J Cell Biochem. 59 (1995); Pp. 317-328; PMID 8567750
• L. Feller, NH Wood, J. Lemmer: HIV -associated Kaposi's sarcoma: pathogenic mechanisms; Oral Surg Oral Med Oral Pathol Oral Radiol Endod. December 1, 2006; PMID 17142074
• A. Crispo, M. Tamburini, MR de Marco, P. Ascierto, P. Silvestro, D. Ronga, V. Tridente, p Desicato, S. Carbone, G. Fabbrocini, D. Spiteri, M. Montella: HHV- 8 prevalence, immunosuppression and Kaposi 's sarcoma in South Italy; Int J Mol Med May 7, 2001; Pp. 535-538; PMID 11295117
• DV Ablashi, LG Chatlynne, JE Whitman, Jr., E. Cesarman: Spectrum of Kaposi 's sarcoma -associated herpesvirus, or human herpesvirus 8, diseases; Clin Microbiol Rev. 15 (2002); Pp. 439-464; PMID 12097251
• E. Guttman - Yassky, J. Dubnov, Z. Kra - Oz, R. Friedman - Birnbaum, M. Silbermann, M. Barchana, R. Bergman, R. Sarid: Classic Kaposi sarcoma. Which KSHV - seropositive individuals are at risk? ; Cancer. 106 (2006); Pp. 413-419; PMID 16353205
• EE Brown, D. Whitby, F. Vitale, V. Marshall, G. Mbisa, C. Gamache, C. Lauria, AJ Alberg, D. Serraino, P. Cordiali - Fei, A. Messina, JJ Goedert: Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma; Cancer. 107 (2006); Pp. 2282-2290; PMID 16998933